Non‐alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance. Issue 8 (31st May 2020)

• Record Type: Journal Article
• Authors: Fiorentino, Teresa Vanessa; Succurro, Elena; Sciacqua, Angela; Andreozzi, Francesco; Perticone, Francesco; Sesti, Giorgio
• Is Part Of: Diabetes/metabolism research and reviews. Volume 36:Issue 8(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-05-31
• Subjects: cardiovascular disease -- coronary artery disease -- non‐alcoholic fatty liver disease -- normal glucose tolerance -- prediabetes -- type 2 diabetes; Diabetes -- Periodicals; Metabolism -- Periodicals; 616.642
• DOI: 10.1002/dmrr.3333
• Languages: English
• ISSNs: 1520-7552

Abstract

Abstarct: Introduction: Non‐alcoholic fatty liver disease (NAFLD) is associated with cardiovascular disease (CVD) in patients with type 2 diabetes; nonetheless, it is unknown whether the relationship between NAFLD and CVD occurs also in subjects with prediabetes. Herein, we evaluated whether NAFLD is associated with prevalent CVD in subjects with different glucose tolerance states independently of cardiovascular risk factors. Materials and methods: Presence of NALFD, defined by liver ultrasound, and its association with prevalent composite and individual CVD, including coronary artery disease (CAD) and cerebrovascular disease, was assessed in a cohort of 1254 Caucasian subjects classified as having normal glucose tolerance (NGT, n = 517), prediabetes (n = 397) or type 2 diabetes (n = 340). Results: Prevalence of NAFLD in the study population was 47.9%. Presence of NAFLD was linked to an augmented prevalence of composite CVD and individual CAD in all the three glucose tolerance groups. In a logistic regression model adjusted for several cardio‐metabolic risk factors, subjects with NGT and NAFLD exhibited a 3.2‐ and 3.4‐fold increased risk of having CVD or CAD, respectively, as compared with those without NAFLD. Similarly, subjects with prediabetes and NAFLD showed an increased risk of having CVD or CAD by 2.3‐ and 2.0‐fold, respectively, in comparison to their counterpart without NAFLD. Within the group with type 2 diabetes, subjects having NAFLD displayed a 2.3‐ and 2.0‐fold higher risk of having CVD or CAD, respectively, in comparison to those without NAFLD. Conclusion: Ultrasonography‐defined NAFLD is independently associated with an increased risk of having CVD in individuals with different glucose tolerance.